Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)

Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):2769-2792. doi: 10.1007/s00210-023-02522-5. Epub 2023 May 23.

Abstract

Lung cancer is the most common type of cancer, with over 2.1 million cases diagnosed annually worldwide. It has a high incidence and mortality rate, leading to extensive research into various treatment options, including the use of nanomaterial-based carriers for drug delivery. With regard to cancer treatment, the distinct biological and physico-chemical features of nano-structures have acquired considerable impetus as drug delivery system (DDS) for delivering medication combinations or combining diagnostics and targeted therapy. This review focuses on the use of nanomedicine-based drug delivery systems in the treatment of lung cancer, including the use of lipid, polymer, and carbon-based nanomaterials for traditional therapies such as chemotherapy, radiotherapy, and phototherapy. The review also discusses the potential of stimuli-responsive nanomaterials for drug delivery in lung cancer, and the limitations and opportunities for improving the design of nano-based materials for the treatment of non-small cell lung cancer (NSCLC).

Keywords: Nanoparticles; Non-small cell lung cancer (NSCLC); Polymeric nanoparticles; Stimuli-responsive nanoparticles.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Drug Carriers / chemistry
  • Drug Delivery Systems
  • Humans
  • Lung Neoplasms* / drug therapy
  • Nanoparticles* / chemistry
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Drug Carriers